tbuckley/cabot-search huggingface dataset:
25482 Secukinumab efficacy and safety profile in pediatric patients with severe chronic plaque psoriasis up to 1 year
Authors: Christine Bodemer, Andrzej Kaszuba, Külli Kingo, Athanasios Tsianakas, Akimichi Morita, Enrique Rivas, Philemon Papanastasiou, Manmath Patekar, Charis Papavassilis, Gerard Bruin, Ruquan You
Journal: Journal of the American Academy of Dermatology (2021)
William Ian Campbell
Authors: John Campbell
Journal: BMJ (2021)

My father, William Ian Campbell, was a recent president of the British Pain Society. He was one of few who worked in anaesthetics, intensive care medicine, and (most of all) chronic pain management.

William Campbell was born in Belfast. He attended five primary schools and two secondary schools, owing to his father’s work in the Royal Ulster Constabulary. On finishing school, he was accepted to study medicine at Queen’s University Belfast, although it was a choice of career between medicine and photography. A mentor in photography told him: “You can work in medicine and have photography as a hobby, but you can’t do it the other way round.”

After graduating he …
Correlation of &lt;sup&gt;11&lt;/sup&gt;C-Methionine Combined Positron Emission and Computed Tomography and Ki-67 Proliferation Index in Pretreatment Assessment of Cerebral Gliomas
Authors: T. Yu. Skvortsova, Zh. I. Savintceva, D. V. Zakhs, A. F. Gurchin, A. I. Kholyavin, Yu. M. Zabrodskaya, T. N. Trofimova
Journal: Radiology - Practice (2021)

The purpose of the study was to explore the correlation between 11С-methionine (Met) uptake measured by combined positron emission and computed tomography (PET/CT) in newly diagnosed cerebral gliomas and tumor proliferative activity as measured by Ki-67 labeling index (Ki-67 LI). The results of PET/CT with 11С-methionine (PET-Met) of 236 adult patients with pretreated glial brain tumors were included in retrospective analysis. The final diagnosis of glioma according to WHO classification of CNS tumors (2007) was based on both histology and immunohistochemistry using Ki-67 antibodies. On PET-Met tumor-to normal brain uptake ratio (TBR) was calculated by dividing maximum Met uptake in the tumor (hot spot 10 mm in diameter) to activity concentration in the contralateral cortex. The Spearmen rank correlation test was used to analyze the relationships between TBR and Ki-67 LI. PET-Met analysis showed that TBR increases with an increase in the aggressiveness of the glial tumor. The differences of TBR values between gliomas grade II vs III and grade III vs IV were significant (p &lt; 0,001). Among grades II-III gliomas Met uptake was significantly higher in oligodendroglial and mixed gliomas than in astrocytomas (p &lt; 0,001), but the differences did not depend on Ki-67 LI. Correlation analysis demonstrated significant correlation between Ki-67 LI and TBR values (r = 0,49, p &lt; 0,05, Spearman rank test). With analyzing glioma subgroups TBR values correlated with Ki-67 LI in diffuse astrocytomas (r = 0,52, p &lt; 0,05), oligodendrogliomas (r = 0,40, p &lt; 0,05), oligoastrocytomas (r = 0,47, p &lt; 0,05) and in high-grade gliomas (r = 0,45, p &lt; 0,05) but not in low-grade gliomas. Comparison between TBR value and Ki-67 LI in each glioma showed a lack of coincidence in 22 % of cases (high Met uptake but low Ki-67 LI and vice versa). The main reasons for such discrepancies were tumor molecular biology or incorrect biopsy target. Met uptake in diffuse gliomas correlates with proliferative activity which justifies the use of PET-Met for glioma grading. In case of mismatch between two biomarkers one should rely on the indicator that implies a higher aggressiveness of the glioma.
Climate action for health and hope
Authors: Renee N Salas, Katharine Hayhoe
Journal: BMJ (2021)

The most serious type of heart attack, an ST elevation myocardial infarction (STEMI), is a life threatening emergency.Once health professionals sound the alarm, an interprofessional team immediately implements critical, time sensitive interventions to help the patient.Focused, oriented actions are the foundation for the evidence based hope in medicine-that intervention can prevent suffering and save lives.
Ian MacGillivray: gynaecologist and obstetrician with expertise in twin pregnancies
Authors: John Illman
Journal: BMJ (2021)

macgillivray110821.f1 



As young boy, Ian MacGillivray, the son of a carpenter, jumped over a fence and broke his arm. Impressed by the doctor who treated him, he went on to win a Carnegie scholarship to read medicine at Glasgow. He later wryly recalled that he had had no previous desire to “save all the suffering in the world” and little idea about what being a doctor involved.

But after starting out as a £100 a year houseman in Falkirk, MacGillivray became globally acclaimed for his study of eclampsia in mothers expecting twins. In 1976 he became president of the International Society for the Study of Hypertension in Pregnancy and, four years later, president of the International Society for Twin Studies.

Where did his early ambitions lie? As a 14 year old he drove his father’s Rover up and down the garage, “got good at changing gears,” and contemplated a career in road surveying or civil engineering—activities he associated with cars.

By this time he had been smoking for five years—not a good omen for a future doctor. Each week he had six pence pocket money: two for sweets and four for a best seat at the cinema. He opted for a two pence seat and two pence for five Woodbine cigarettes. After smoking 50 cigarettes a day …
Patient-Centered Goal-Setting in the National Diabetes Prevention Program: A Pilot Study
Authors: Natalie D. Ritchie, Katherine A. Sauder, Peter G. Kaufmann, Leigh Perreault
Journal: Diabetes Care (2021)

Difficulty achieving preset goals (e.g., ≥5% weight loss, ≥150 min of weekly physical activity) in the yearlong National Diabetes Prevention Program (NDPP) can prompt dropout and diminish benefits. We piloted a more patient-centered NDPP adaptation (NDPP-Flex) that promotes a variety of attainable and individually tailored goals to reduce diabetes risks, along with flexibility to adjust goals each week as needed.Retention, physical activity, weight, and glycated hemoglobin (HbA1c) were evaluated among diverse participants with diabetes risks who received our pilot of NDPP-Flex beginning in January and July 2018 (n = 95), with a planned comparison with standard NDPP delivery in preceding cohorts that launched between September 2016 and October 2017 (n = 245). Both the standard NDPP and NDPP-Flex interventions were 1 year in duration and implemented in phases (i.e., nonrandomized).Average adjusted retention (e.g., 158.90 ± 15.20 vs. 166.71 ± 9.38 days; P = 0.674), physical activity (157.97 ± 11.91 vs. 175.64 ± 7.54 weekly min; P = 0.231), and weight loss (1.46 ± 0.38% vs. 1.90 ± 0.24%; P = 0.396) were similar between NDPP-Flex versus standard NDPP. However, NDPP-Flex participants had greater HbA1c reduction on average (0.22 ± 0.05% vs. 0.06 ± 0.03%; P = 0.018) and were more likely to have normoglycemia at follow-up (odds ratio 4.62; P = 0.013 [95% CI 1.38-15.50]) than participants in the standard NDPP.An adapted, more patient-centered NDPP that focuses on flexible, self-selected goals may be a promising strategy to improve glycemia even in the absence of substantial weight loss.
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
Authors: Daniel S Reich, Douglas L Arnold, Patrick Vermersch, Amit Bar-Or, Robert J Fox, Andre Matta, Timothy Turner, Erik Wallström, Xinyan Zhang, Miroslav Mareš, Farit A Khabirov, Anthony Traboulsee, Francois Grand'Maison, Francois Jacques, Anthony Traboulsee, Michaela Tyblova, Eva Meluzinova, Radek Ampapa, Martin Valis, Pavel Hradilke, Miroslav Mareš, Pavel Stourac, Katrin Gross-Paju, David Laplaud, Guillaume Mathey, Bernard Uitdehaag, Evgeny Evdoshenkoo, Ekaterina Popova, Maria Zakharova, Natalia Totolyan, Igor Litvinenko, Farit Khabirov, Stella Sivertseva, Viera Hancinova, Ema Kantorova, Maria Luisa Martinez Gines, Xavier Montalban, Sara Eichau Maduano, Jose Meca-Lallana, Lluís Ramió-Torrentà, Tetyanna Nehrych, Valeriy Pashkovskyy, Sergii Moskovko, Oleksandr Kalbus, Marta Khavunka, Volodymyr Pryshchepa, Alla Goloborodko, Daniel Wynn, William Honeycutt, Sibyl Wray, Brian Steingo, Christopher LaGanke, Deren Huang, John Michael Hemphill, Lawrence Goldstick, Derrick Robertson
Journal: The Lancet Neurology (2021)
Abstract 15192: Out of Hospital Arrest: Are We Performing Coronary Angiography Often Enough?
Authors: Niranjan J Gaikwad, Rohan Jayasinghe, Greg Aroney, Gregory Comadira, Jon Field
Journal: Circulation (2012)

Objective: To determine the etiologies, coronary angiography results and survival of patients admitted to the Intensive Care Unit (ICU) at the Gold Coast Hospital, after out of hospital cardiac arr...
US Health Care Spending by Race and Ethnicity, 2002-2016
Authors: Joseph L. Dieleman, Carina Chen, Sawyer W. Crosby, Angela Liu, Darrah McCracken, Ian A. Pollock, Maitreyi Sahu, Golsum Tsakalos, Laura Dwyer-Lindgren, Annie Haakenstad, Ali H. Mokdad, Gregory A. Roth, Kirstin Woody Scott, Christopher J. L. Murray
Journal: JAMA (2021)

Measuring health care spending by race and ethnicity is important for understanding patterns in utilization and treatment.
Wnt5b expression: A novel candidate predictive factor for disease evolution in chronic lymphocytic leukemia
Authors: Cristina Rabascio, Luca Saronni, Valentina Raia, Patrizia Mancuso, Alice Agliano, Cinzia Massaro, Daniele Laszlo, Giovanni Martinelli, Francesco Bertolini
Journal: Cancer Research (2006)

1139  Background: Molecular diagnostic tools offer the potential for accurate prognostic road maps in patients with hematological malignancies. Wnts are a large family of secreted glycoproteins involved in cell proliferation, differentiation and oncogenesis. The classical Wnt signaling cascade inhibits the activity of the enzyme glycogen synthase kinase-3beta, augmenting beta-catenin translocation to the nucleus and the transcription of target genes. Previous data (Desheng et al PNAS 2004) suggested that the Wnt signaling pathway contributes to a deficient apoptosis in chronic lymphocytic leukemia (CLL). Method: In this retrospective study we used the ABI PRISM 7000 Real Time platform to analyze the Wnt5b gene expression in 24 newly diagnosed CLL patients randomly chosen from our database. Patients were treated with different treatment schedules. In addition we analyzed 9 hematological neoplastic cell lines and 18 healthy donors. Wnt5b pathologic expression was then normalized against healthy donors median expression (P/H). Results: All healthy donors and cell lines and 15 CLL patients showed Wnt5b expression, while 9 CLL patients were negative. After a median follow up of 22 months (range 8-29), 6 patients were in complete remission (CR), 11 were in stable disease (SD) and 7 had progressive disease (PD). In this patient population, 14/15 patients (93%) with Wnt5b basal expression were in PD or SD (p=0.01 vs patients in CR). All patients who achieved a CR after therapy had no or very low Wnt5b expression at diagnosis (median P/H=0, range 0-0.26), while SD or PD patients had a median P/H ratio higher than 0.3 (range 0-10.52, p=0.03). Since other investigators have described Wnt5b expression in CD19+ neoplastic B cells, we next investigated Wnt5b expression in CD19+, CD14+, CD3+ and CD56+ cells from healthy donors purified by magnetic beads (purity >90%). In healthy donors Wnt5b was expressed only in purified CD14+ monocyte cell fraction and not in CD19+ (B-cells), CD3+ (T-cells) or CD56+ (NK-cells) or in the remaining CD14-negative cell fraction. Conclusion: In our CLL patient population, Wnt5b expression at diagnosis was a negative predictive factor associated to disease evolution. We are currently prospectively evaluating a larger patient population to better assess in multivariate analysis the predictive potential of this novel biomarker along with established prognostic factors such as ZAP70 expression and mutational status. The availability of this potential biologic prognostic indicator might be of great importance for future risk-adapted treatments. Further prospective studies evaluating the different technologic aspects of its detection and correlation with other biological markers (ZAP70 and mutational status) are clearly needed to confirm our preliminary results.
High Expression of MEF2D-Fusion Protein Is Caused By Escaping from the Suppression By miRNA and Leads to Suppress Transcriptional Activity of PAX5
Authors: Hirano Daiki, Fumihiko Hayakawa, Takahiko Yasuda, Naoyuki Tange, Hideyuki Yamamoto, Yuki Kojima, Takanobu Morishita, Naoto Imoto, Shinobu Tsuzuki, Hiroyuki Mano, Tomoki Naoe, Hitoshi Kiyoi
Journal: Blood (2017)
A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants
Authors: Aaron J. Schmitz, Jackson S. Turner, Zhuoming Liu, Julian Q. Zhou, Ishmael D. Aziati, Rita E. Chen, Astha Joshi, Traci L. Bricker, Tamarand L. Darling, Daniel C. Adelsberg, Clara G. Altomare, Wafaa B. Alsoussi, James Brett Case, Laura A. VanBlargan, Tingting Lei, Mahima Thapa, Fatima Amanat, Trushar Jeevan, Thomas Fabrizio, Jane A. O’Halloran, Pei-Yong Shi, Rachel M. Presti, Richard J. Webby, Florian Krammer, Sean P.J. Whelan, Goran Bajic, Michael S. Diamond, Adrianus C.M. Boon, Ali H. Ellebedy
Journal: Immunity (2021)
The Helping to End Addiction Long-term (HEAL) Initiative of the National Institutes of Health
Authors: Rebecca G. Baker, Walter J. Koroshetz, Nora D. Volkow
Journal: JAMA (2021)

This Viewpoint discusses the Helping to End Addiction Long-term initiative of the National Institutes of Health that was launched in 2018 to provide scientific solutions to the evolving crisis of opioid misuse, addiction, and overdose.
Association of the COVID-19 Pandemic With the Prevalence of Homebound Older Adults in the United States, 2011-2020
Authors: Claire K. Ankuda, Bruce Leff, Christine S. Ritchie, Albert L. Siu, Katherine A. Ornstein
Journal: JAMA Internal Medicine (2021)

opioids months later?We do know that indiscriminate opioid use has been responsible for a lot of pain, suffering, and death in the US, and we must seriously consider any and all attempts to relieve the pain and suffering associated with overuse of opioids.Restricting initial prescriptions to 7 or fewer days is reasonable because patients with new onset of pain should be reevaluated in a week if the pain continues.But we worry that restricting initial prescriptions to shorter periods, such as 3 or 5 days, as occurred in 6 states in this study, may result in patients with acute pain going untreated or having to go to extraordinary effort to obtain adequate pain relief.We think the data in this study 4 suggest that limiting initial prescriptions to 7 or fewer days is helpful, but we would not restrict any further given that we do not know how it affected patients with acute pain.
Theranostic Heterodimeric Prodrug with Dual‐Channel Fluorescence Turn‐On and Dual‐Prodrug Activation for Synergistic Cancer Therapy
Authors: Maolin Jiang, Kewei Wang, Xuan Xiao, Qingyu Zong, Rui Zheng, Youyong Yuan
Journal: Advanced Healthcare Materials (2021)

Abstract Theranostic prodrugs that can precisely monitor drug activation with synergistic therapeutic effects are highly desirable for personalized medicine. In this study, a theranostic heterodimeric prodrug, CyNH‐SS‐DOX, with synchronous and independent dual‐channel fluorescence turn‐on and dual‐prodrug activation for synergistic cancer therapy is developed. A hemicyanine fluorescent drug, CyNH 2 , with good therapeutic effects found in this work, is conjugated to doxorubicin (DOX) through a disulfide linker to form CyNH‐SS‐DOX. Before activation, both the fluorescence of DOX and CyNH 2 are in the off state and the toxicity is low. In the presence of intracellular glutathione, both the fluorescence of DOX and CyNH 2 at different channels are turned on. Meanwhile, DOX and CyNH 2 are activated in a synergistic anticancer effect. It is believed that CyNH‐SS‐DOX is promising for monitoring prodrug activation in dual‐fluorescence channels and for enhancing therapeutic efficacy with few side effects.
26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
Authors: Maryanne M. Senna, Amy J. McMichael, Tiffany T. Mayo, Julian Mackay-Wiggan, Marc Glashofer, Luna Sun, Guanglei Yu, Fabio P. Nunes, Jill S. McCollam, Wen-Shuo Wu, Brett King
Journal: Journal of the American Academy of Dermatology (2021)
Long-term impact of COVID-19 associated acute respiratory distress syndrome
Authors: Judit Aranda, Isabel Oriol, Miguel Martín, Lucía Feria, Núria Vázquez, Nicolás Rhyman, Estel Vall-Llosera, Natàlia Pallarés, Ana Coloma, Melani Pestaña, Jose Loureiro, Elena Güell, Beatriz Borjabad, Elena León, Elena Franz, Anna Domènech, Sara Pintado, Anna Contra, María del Señor Cortés, Iván Chivite, Raquel Clivillé, Montserrat Vacas, Luis Miguel Ceresuela, Jordi Carratalà
Journal: Journal of Infection (2021)

To determine the health status, exercise capacity, and health related quality of life (HRQoL) of COVID-19 associated acute respiratory distress syndrome (ARDS) survivors, 8 months after diagnosis.All eligible patients were interviewed and underwent a physical examination, chest X-ray, and 6 min walk test (6MWT). Scales to evaluate post-traumatic stress disorder, depression, anxiety, and HRQoL were applied.Of 1295 patients, 365 suffered ARDS and 166 survived to hospital discharge. Five died after discharge and 48 were lost to follow-up. Of the 113 remaining patients, 81% had persistent symptoms. More than 50% of patients completed less than 80% of the theoretical distance on the 6MWT, 50% had an abnormal X-ray and 93% of patients developed psychiatric disorders. Mean SF-36 scores were worse than in the general population. After multivariate regression analysis, female sex, non-Caucasian race, and Charlson index>2 were independent risk factors for a worse mental health component summary score on the SF-36, and age was associated with a better prognosis. Female sex and chronic obstructive pulmonary disease were independently associated with a worse physical component summary score.COVID-19 associated ARDS survivors have long-term consequences in health status, exercise capacity, and HRQoL. Strategies addressed to prevent these sequelae are needed.
The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis
Authors: Shan-Shan Liu, Chang Liu, Xiao-Xi Lv, Bing Cui, Jun Yan, Yun-Xuan Li, Ke Li, Fang Hua, Xiao-Wei Zhang, Jiao-Jiao Yu, Jin-Mei Yu, Feng Wang, Shuang Shang, Ping-Ping Li, Zhi-Guang Zhou, Yang Xiao, Zhuo-Wei Hu
Journal: Immunity (2021)
Breast Carcinoma Shown on 99mTc-HYNIC-TOC Study Performed to Evaluate Tumor-Induced Osteomalacia
Authors: Xiaona Jin, Fang Li, Libo Chen, Hongli Jing
Journal: Clinical Nuclear Medicine (2021)

A 74-year-old woman with a history of suspected tumor-induced osteomalacia underwent 99mTc-HYNIC-TOC scintigraphy to search potential culprit tumor. The images showed one in the middle shaft of left femur without corresponding morphology change on the CT portion of the subsequent SPECT/CT images. The patient declined surgical exploration of the left femur. Another activity was in the right breast, which was resected and pathologically confirmed as breast carcinoma. Postsurgically, the patient's symptoms were not improved. Four years later, a repeat 99mTc-HYNIC-TOC scintigraphy showed more prominent activity in the left femur with gross abnormality on the corresponding CT images.
Construction of hollow polydopamine nanoparticle based drug sustainable release system and its application in bone regeneration
Authors: Lu Wang, Shuwei Liu, Chunxia Ren, Siyuan Xiang, Daowei Li, Xinqing Hao, Shilei Ni, Yixin Chen, Kai Zhang, Hongchen Sun
Journal: International Journal of Oral Science (2021)

Abstract Nanomaterial-based drug sustainable release systems have been tentatively applied to bone regeneration. They, however, still face disadvantages of high toxicity, low biocompatibility, and low drug-load capacity. In view of the low toxicity and high biocompatibility of polymer nanomaterials and the excellent load capacity of hollow nanomaterials with high specific surface area, we evaluated the hollow polydopamine nanoparticles (HPDA NPs), in order to find an optimal system to effectively deliver the osteogenic drugs to improve treatment of bone defect. Data demonstrated that the HPDA NPs synthesized herein could efficiently load four types of osteogenic drugs and the drugs can effectively release from the HPDA NPs for a relatively longer time in vitro and in vivo with low toxicity and high biocompatibility. Results of qRT-PCR, ALP, and alizarin red S staining showed that drugs released from the HPDA NPs could promote osteogenic differentiation and proliferation of rat bone marrow mesenchymal stem cells (rBMSCs) in vitro. Image data from micro-CT and H&amp;E staining showed that all four osteogenic drugs released from the HPDA NPs effectively promoted bone regeneration in the defect of tooth extraction fossa in vivo, especially tacrolimus. These results suggest that the HPDA NPs, the biodegradable hollow polymer nanoparticles with high drug load rate and sustainable release ability, have good prospect to treat the bone defect in future clinical practice.